Full Press Release Details
Announces Publication of EGM Circular in Respect of Proposed Conversion
to Direct Listing of its Shares on NASDAQ
DUBLIN--(BUSINESS WIRE)--November 16, 2012--ICON plc, (NASDAQ: ICLR)
(ISIN:IE0005711209), a global provider of outsourced development
services to the pharmaceutical, biotechnology and medical device
industries, today announced the publication and filing of a circular to
shareholders convening an extraordinary general meeting to be held at
3.00 p.m. on December 17, 2012 at ICON plc Headquarters, South County
Business Park, Leopardstown, Dublin 18, Ireland at which resolutions in
connection with the proposed replacement of ICON's NASDAQ listing for
ADSs with a direct NASDAQ listing for ICON Shares will be considered and
The expected timetable in respect of the proposals is as follows:
| Latest time and date for receipt of Forms of Proxy for Ordinary Shareholders for Extraordinary General Meeting | 13 December 2012 (6 p.m. GMT) | |||
| Extraordinary General Meeting | 17 December 2012 (3 p.m. GMT) | |||
| Expected last day of dealings in Shares on Irish Stock Exchange | 29 January 2013 | |||
| Expected date of Irish Stock Exchange Delisting with effect from 6.30 a.m. (GMT) | 30 January 2013 | |||
| Expected date of commencement of direct trading of Shares on NASDAQ | 4 February 2013 |
A copy of the Circular is available in the investor relations section of
ICON's website at http://investor.iconplc.com/proxy.cfm.
A copy of the Circular is also being submitted to the Irish Stock
Exchange, and will shortly be available for inspection at:
Company Announcements Office,
Irish Stock Exchange,
Defined terms used in this announcement have the same meaning as in the
Circular unless otherwise stated.
The information contained in this release is as of November 16th
2012. ICON assumes no obligation to update forward-looking statements
contained in this release. A description of risks and uncertainties
relating to ICON and its business can be found in ICON's Annual Report
and Form 20-F for the fiscal year ended December 31, 2011 and in its
Reports of Foreign Issuer on Form 6-K filed with the US Securities and
Exchange Commission.
ICON plc is a global provider of outsourced development services to the
pharmaceutical, biotechnology and medical device industries. The company
specialises in the strategic development, management and analysis of
programs that support clinical development - from compound selection to
Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON
currently, operates from 82 locations in 40 countries and has
approximately 9,430 employees. Further information is available at http://www.iconplc.com.
Chief Financial Officer
VP Investor Relations